The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Investigation

• Publication date

  2014-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1172/JCI75276PMID 25202980PMCID PMC4215190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation.

  2016cited by this paper
• Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.

  2014cited by this paper
• The choroid plexus: a comprehensive review of its history, anatomy, function, histology, embryology, and surgical considerations

  2014cited by this paper
• Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.

  2014cited by this paper
• Hormones and diet, but not body weight, control hypothalamic microglial activity

  2014cited by this paper
• Hypothalamic tanycytes are an ERK-gated conduit for leptin into the brain.

  2014cited by this paper
• Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.

  2014cited by this paper
• Hypothalamic Inflammation: Marker or Mechanism of Obesity Pathogenesis?

  2013cited by this paper
• Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

  2013cited by this paper
• In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis

  2013cited by this paper
• Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

  2013cited by this paper
• Exenatide-Induced Reduction in Energy Intake Is Associated With Increase in Hypothalamic Connectivity

  2013cited by this paper
• Tanycyte‐like cells form a blood–cerebrospinal fluid barrier in the circumventricular organs of the mouse brain

  2013cited by this paper
• GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

  2013cited by this paper
• The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty.

  2013cited by this paper
• Functionally biased signalling properties of 7TM receptors – opportunities for drug development for the ghrelin receptor

  2013cited by this paper
• Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

  2013influential reference
• Rapid sensing of circulating ghrelin by hypothalamic appetite-modifying neurons

  2013influential reference
• Towards improved receptor targeting: anterograde transport, internalization and postendocytic trafficking of neuropeptide Y receptors

  2013cited by this paper
• Gastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats.

  2012cited by this paper
• Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis

  2012cited by this paper
• Obesity and Appetite Control

  2012cited by this paper
• Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight

  2012influential reference
• Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.

  2012cited by this paper
• GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake.

  2012cited by this paper
• Chemical Clearing and Dehydration of GFP Expressing Mouse Brains

  2012cited by this paper
• GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

  2012cited by this paper
• Vagal Afferents Mediate Early Satiation and Prevent Flavour Avoidance Learning in Response to Intraperitoneally Infused Exendin‐4

  2012cited by this paper
• Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro.

  2012cited by this paper
• Obesity is associated with hypothalamic injury in rodents and humans.

  2012cited by this paper
• Different vascular permeability between the sensory and secretory circumventricular organs of adult mouse brain

  2012influential reference
• Arcuate AgRP neurons and the regulation of energy balance

  2012cited by this paper
• Exendin-4 decreases amphetamine-induced locomotor activity.

  2012cited by this paper
• The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

  2011cited by this paper
• Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive fashion

  2011cited by this paper
• The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1.

  2011cited by this paper
• Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs

  2011cited by this paper
• GLP-1 and energy balance: an integrated model of short-term and long-term control

  2011cited by this paper
• Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation.

  2011cited by this paper
• The arcuate nucleus as a circumventricular organ in the mouse.

  2011cited by this paper
• Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake

  2011cited by this paper
• Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

  2011influential reference
• Leptin receptor expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice.

  2011cited by this paper
• Hyperphagia and Increased Fat Accumulation in Two Models of Chronic CNS Glucagon-Like Peptide-1 Loss of Function

  2011cited by this paper
• Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4.

  2011influential reference
• Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist.

  2010cited by this paper
• The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid.

  2010cited by this paper
• Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides.

  2010cited by this paper
• The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

  2010influential reference
• Differential gene expression between neuropeptide Y expressing neurons of the dorsomedial nucleus of the hypothalamus and the arcuate nucleus: microarray analysis study.

  2010cited by this paper
• Leptin Directly Depolarizes Preproglucagon Neurons in the Nucleus Tractus Solitarius

  2010cited by this paper
• Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

  2009cited by this paper
• Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms.

  2009influential reference
• Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

  2009cited by this paper
• Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling.

  2009influential reference
• Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.

  2009cited by this paper
• Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats

  2009influential reference
• Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents.

  2009cited by this paper
• Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing

  2008cited by this paper
• Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation.

  2008cited by this paper
• Protein components of the blood-brain barrier (BBB) in the mediobasal hypothalamus.

  2008cited by this paper
• Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake

  2008influential reference
• Upregulation of the brainstem preproglucagon system in the obese Zucker rat.

  2008cited by this paper
• Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not

  2007cited by this paper
• Liraglutide, a Once‐daily Human Glucagon‐like Peptide‐1 Analog, Minimizes Food Intake in Severely Obese Minipigs

  2007cited by this paper
• The physiology of glucagon-like peptide 1.

  2007cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Serotonin reciprocally regulates melanocortin neurons to modulate food intake.

  2006cited by this paper
• NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates

  2005cited by this paper
• Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

  2005cited by this paper
• A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

  2004cited by this paper
• A new obesity-prone, glucose-intolerant rat strain (F.DIO).

  2003cited by this paper
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

  2003cited by this paper
• Involvement of the Arcuate Nucleus of the Hypothalamus in Interleukin-1-Induced Anorexia

  2002cited by this paper
• Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.

  2002cited by this paper
• Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier

  2002influential reference
• A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

  2001cited by this paper
• Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

  2001cited by this paper
• The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake

  2000cited by this paper
• Central nervous system control of food intake

  2000influential reference
• Food intake and the regulation of body weight.

  2000influential reference
• Recombinant CART peptide induces c-Fos expression in central areas involved in control of feeding behaviour.

  1999cited by this paper
• Distribution of pre‐pro‐glucagon and glucagon‐like peptide‐1 receptor messenger RNAs in the rat central nervous system

  1999cited by this paper
• The glucagon-like peptides.

  1999cited by this paper
• PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats.

  1998cited by this paper
• Hypothalamic CART is a new anorectic peptide regulated by leptin

  1998cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

  1997influential reference
• OB protein binds specifically to the choroid plexus of mice and rats.

  1996cited by this paper
• Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

  1996cited by this paper
• Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

  1996cited by this paper
• A role for glucagon-like peptide-1 in the central regulation of feeding

  1996influential reference
• Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I

  1996cited by this paper
• Intracellular Cl activity: evidence of dual mechanisms of cl absorption in sweat duct.

  1994cited by this paper
• A method for selective section of vagal afferent or efferent axons in the rat.

  1994cited by this paper
• Microvascular density of the human paraventricular nucleus decreases with aging but not hypertension.

  1993cited by this paper
• The induction of obesity in rodents by means of monosodium glutamate

  1976cited by this paper

• GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization.

  2026cites this paper
• Limited Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Appetite and Body Weight: Evidence From Clinical and Rodent Studies

  2026cites this paper
• Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system.

  2026cites this paper
• D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice.

  2026cites this paper
• Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review

  2026cites this paper
• The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications

  2026cites this paper
• Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review

  2026cites this paper
• GLP-1 physiology and pharmacology along the gut-brain axis

  2026influential citation
• Obesity medications and acquired hypothalamic obesity in adults: A two-case experience

  2026cites this paper
• Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents With Variants in Monogenic Obesity‐Related Genes

  2026cites this paper
• Metabolic sexual dimorphism in hypothalamic Fezf1 neuron-specific BDNF knockout

  2025cites this paper
• The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus

  2025cites this paper
• Effectiveness and safety of GLP‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study

  2025cites this paper
• Insights into the Mechanism of Action of Tirzepatide: A Narrative Review

  2025cites this paper
• Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy.

  2025cites this paper
• Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence

  2025cites this paper
• Brain-Derived GLP-1—Understanding the Physiological Function and Anti-obesity Potential of Preproglucagon Neurons

  2025cites this paper
• Obesity: assessment and treatment across the care continuum

  2025cites this paper
• Pharmacotherapies for Binge Eating Disorder: Systematic Review and Network Meta‐Analysis

  2025cites this paper
• GLP-1 and ghrelin inversely regulate insulin secretion and action in pancreatic islets, vagal afferents and hypothalamus for controlling glycemia and feeding.

  2025cites this paper
• Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone

  2025cites this paper
• Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists

  2025cites this paper
• Neuroendocrinology and Genetics of Obesity.

  2025cites this paper
• A Perfect MASH Comparing Resmetirom and GLP-1 Agonists for Metabolic-Associated Steatohepatitis: What Does the Current Evidence Suggest?

  2025cites this paper
• Glucagon-like peptide 1 (GLP-1) action on hypothalamic feeding circuits.

  2025cites this paper
• Pharmacotherapy for Obesity: Recent Updates

  2025cites this paper
• Hypothalamic regulation of obesity: Revealing the therapeutic potential of a novel anti-obesity peptide.

  2025cites this paper
• Psychological and behavioral effects of GLP-1 and GIP agonists in weight loss: a comprehensive review

  2025cites this paper
• Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection

  2025cites this paper
• Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder

  2025cites this paper
• The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis

  2025cites this paper
• Advancements and challenges in the management of obesity using pharmacotherapy (Review)

  2025cites this paper
• Non-caloric sweetener effects on brain appetite regulation in individuals across varying body weights

  2025cites this paper
• Gut Microbiome Regulation of Gut Hormone Secretion

  2025cites this paper
• Exploring Side Effects and Discontinuation Reasons of Glucagon-Like-Peptide-1 Agonist (Liraglutide, Semaglutide) for Weight Loss Among Patients at King Abdulaziz University, Jeddah in 2021 to 2023

  2025cites this paper
• Fam163a knockdown and mitochondrial stress in the arcuate nucleus of hypothalamus reduce AgRP neuron activity and differentially regulate mitochondrial dynamics in mice

  2025cites this paper
• Unraveling neural underpinnings of eating disorders in the female brain: insights from high-field magnetic resonance imaging.

  2025cites this paper
• GLP-1 receptor agonist exendin-4 suppresses food intake by inhibiting hindbrain orexigenic NPY neurons.

  2025cites this paper
• Incretin-based therapeutics for the treatment of neurodegenerative diseases

  2025influential citation
• Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis

  2025cites this paper
• Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review

  2025cites this paper
• Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies

  2025influential citation
• Recent advances in the pharmacological treatment of obesity

  2025cites this paper
• Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis

  2025cites this paper
• Central neuropeptides as key modulators of astrocyte function in neurodegenerative and neuropsychiatric disorders

  2025cites this paper
• The Antidipsogenic Action of Nesfatin-1 Requires Activation of a GLP-1 Receptor.

  2025cites this paper
• The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies

  2025cites this paper
• Crossing Barriers: Advancements in Macromolecular Therapeutics for Neurodegenerative Diseases and Strategies to Overcome the Blood-Brain Barrier.

  2025cites this paper
• GLP-1 agonists: a game changer in pain treatment and addiction.

  2025cites this paper
• Proglucagon-derived Peptides: Human Physiology and Therapeutic Potential.

  2025cites this paper
• Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice

  2025influential citation
• Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects

  2025cites this paper
• Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide.

  2025cites this paper
• Die Brücke zwischen Labor und Klinik: Wie humangenetische Untersuchungen die Therapie bei genetischer Adipositas leiten

  2025cites this paper
• The estrous cycle moderates the food and body weight suppressive effects of glucagon‐like peptide‐1 receptor agonism

  2025cites this paper
• Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases

  2025cites this paper
• Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons

  2025cites this paper
• Diet context gates AgRP neuron involvement in Semaglutide-induced weight loss

  2025cites this paper
• Tirzepatide for adults living with obesity.

  2025cites this paper
• Semaglutide for adults living with obesity.

  2025cites this paper
• The science of obesity.

  2025cites this paper
• Pharmacotherapy for obesity management.

  2025cites this paper
• Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review

  2025cites this paper
• Upcoming drug targets for kidney protective effects in chronic kidney disease

  2025cites this paper
• Hallmarks of Appetite: A Comprehensive Review of Hunger, Appetite, Satiation, and Satiety

  2025cites this paper
• Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus

  2025cites this paper
• Understanding the release mechanisms and secretion patterns for glucagon-like peptide-1 using the isolated perfused intestine as a model

  2025cites this paper
• A comprehensive spatio-cellular map of the human hypothalamus

  2025influential citation
• Integration of Glucagon-like Peptide 1 Receptor Actions through the Central Amygdala.

  2025cites this paper
• Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder

  2025cites this paper
• Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity

  2025cites this paper
• Nmnat2 deficiency in the arcuate nucleus or paraventricular nucleus induces Sarm1‐independent neuron loss and liraglutide‐reversible obesity

  2025influential citation
• Glucose-dependent insulinotropic polypeptide (GIP)

  2025cites this paper
• The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines

  2025cites this paper
• Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss

  2025cites this paper
• Effects of glucagon‐like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta‐analysis

  2025cites this paper
• Sex differences in GLP-1 signaling across species

  2025cites this paper
• Exendin-4 improves cerebral ischemia by relaxing microvessels, rapidly increasing cerebral blood flow after reperfusion

  2025cites this paper
• The neurobiology of overeating.

  2025cites this paper
• Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review

  2025cites this paper
• Exendin-4(1-32)K-Capric Acid, a Glucagon-Like Peptide-1 Receptor Agonist, Suppresses Food Intake via Arcuate Pro-Opiomelanocortin Neurons

  2025cites this paper
• Depressive symptoms at short‐, medium‐, and long‐term follow‐up after bariatric surgical procedures: A systematic review and meta‐analysis

  2025cites this paper
• Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• On the Pleiotropic Actions of Glucagon-like Peptide-1 in Its Regulation of Homeostatic and Hedonic Feeding

  2025cites this paper
• Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease

  2025cites this paper
• GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice

  2025cites this paper
• Comparing the anorexigenic effects and mechanisms of gut-derived GLP-1 and its receptor agonists: insights into incretin-based therapies for obesity

  2025cites this paper
• Smoking, Obesity, and Post-Cessation Weight Gain: Neurobiological Intersection and Treatment Recommendations

  2025cites this paper
• Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy

  2025cites this paper
• GLP-1-based medications: Mechanisms involved in obesity treatment.

  2025cites this paper
• Traditional Chinese medicine modulates hypothalamic neuropeptides for appetite regulation: A comprehensive review.

  2025cites this paper
• Liraglutide improves depressive and cognitive deficits in a high-fat diet rat model of obesity: the role of hippocampal autophagy and the PI3K/Akt/mTOR pathway

  2025cites this paper
• Recent Progress in the Pharmacotherapy for Obesity.

  2025cites this paper
• Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy

  2025cites this paper
• The expanding role of semaglutide: beyond glycemic control

  2025cites this paper
• The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways

  2025influential citation
• The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats

  2025cites this paper
• Liraglutide Induces Enhanced Suppression of Food Intake in Mice Lacking the Growth Hormone Secretagogue Receptor.

  2025cites this paper
• Effects of tryptophan-selective lipidated GLP-1 peptides on the GLP-1 receptor.

  2025cites this paper